Congreso EAACI 2024: Innovación y Avances en el Tratamiento de Alergias
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Durante el congreso se presentarán más de 150 sesiones científicas centradas en los avances en ciencia medioambiental, alergias alimentarias, innovaciones en inmunoterapia o alergias pediátricas,...
欧州アレルギー・臨床免疫学会2024 (EAACI Congress 2024)：アレルギー治療の革新と進歩
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
学会中は、環境科学の進歩、食物アレルギー、免疫療法の革新、小児アレルギーなどに焦点を当てた、150を超える科学セッションが開催される。精密医療、AI、免疫療法、免疫調節剤が、最大規模のアレルギーおよび免疫学学会に集結。同学会は、5月31日から6月3日までスペインのバレンシアで開催される。 スペイン、バレンシア発, April 30, 2024 (GLOBE NEWSWIRE) --...
Kongres EAACI 2024: Inovasi dan Kemajuan dalam Pengobatan Alergi
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Lebih dari 150 sesi ilmiah akan dipresentasikan selama pelaksanaan kongres, dengan fokus di berbagai bidang yang di antaranya mencakup kemajuan dalam sains lingkungan, alergi makanan, inovasi...
קונגרס EAACI 2024: חדשנות והתקדמות בטיפול באלרגיה
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
במהלך הקונגרס יוצגו למעלה מ-150 מושבים מדעיים, שיתמקדו בין היתר בהתקדמות במדעי הסביבה, אלרגיות למזון, חידושים באימונותרפיה ואלרגיות ילדים.רפואה מדויקת, בינה מלאכותית, אימונותרפיה ומודולטורים...
Congrès EAACI 2024 : innovations et progrès dans le traitement des allergies
April 30, 2024 02:58 ET
|
European Academy of Allergy and Clinical Immunology
Lors de ce congrès, plus de 150 sessions scientifiques seront présentées. Les sujets abordés se concentreront sur les progrès de la science environnementale, les allergies alimentaires, les...
Medigene AG reports Financial Results and Business Update for Q1 2024
April 26, 2024 03:00 ET
|
Medigene AG
Planegg/Martinsried, April 26, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Medigene presents streamlined 6-day, high stemness TCR-T therapy production process
April 25, 2024 09:00 ET
|
Medigene AG
Planegg/Martinsried, April 25, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...
Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Medigene to Present at Upcoming Scientific Conferences
April 17, 2024 06:00 ET
|
Medigene AG
Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, has been...
Medigene Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024
April 08, 2024 02:00 ET
|
Medigene AG
Planegg/Martinsried, April 8, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...